Search research articles
Contact Us
Filters
Showing results (71-80 of 92) with videos related to
Page
of 10
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 22, 2009
Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models
J S Vermaat, I van der Tweel, N Mehra, et al.
British Journal of Cancer
|
August 24, 2013
MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours
C M M Gits, P F van Kuijk, M B E Jonkers, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 13, 2013
Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study
H Gelderblom, J Y Blay, B M Seddon, et al.
Frontiers in Oncology
|
July 12, 2021
Prospective Evaluation of a Circulating Tumor Cell Sensitivity Profile to Predict Response to Cisplatin Chemotherapy in Metastatic Breast Cancer Patients
I E de Kruijff, A M Sieuwerts, N Beije, et al.
British Journal of Cancer
|
June 5, 2015
Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial
N Beije, J Kraan, W Taal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 29, 2016
The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies
G A Cirkel, F Weeber, S Bins, et al.
British Journal of Cancer
|
April 17, 2014
Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours
N A G Lankheet, J S L Kloth, C G M Gadellaa-van Hooijdonk, et al.
Scientific Reports
|
July 3, 2023
The genomic and transcriptomic landscape of advanced renal cell cancer for individualized treatment strategies
K de Joode, W S van de Geer, G J L H van Leenders, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 5, 2014
Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients
B Mostert, A M Sieuwerts, J Kraan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 1, 2019
Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients
S B van Waalwijk van Doorn-Khosrovani, A Pisters-van Roy, L van Saase, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 92) with videos related to
Sort By:
Page
of 10
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 22, 2009
Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models
J S Vermaat, I van der Tweel, N Mehra, et al.
British Journal of Cancer
|
August 24, 2013
MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours
C M M Gits, P F van Kuijk, M B E Jonkers, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 13, 2013
Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study
H Gelderblom, J Y Blay, B M Seddon, et al.
Frontiers in Oncology
|
July 12, 2021
Prospective Evaluation of a Circulating Tumor Cell Sensitivity Profile to Predict Response to Cisplatin Chemotherapy in Metastatic Breast Cancer Patients
I E de Kruijff, A M Sieuwerts, N Beije, et al.
British Journal of Cancer
|
June 5, 2015
Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial
N Beije, J Kraan, W Taal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 29, 2016
The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies
G A Cirkel, F Weeber, S Bins, et al.
British Journal of Cancer
|
April 17, 2014
Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours
N A G Lankheet, J S L Kloth, C G M Gadellaa-van Hooijdonk, et al.
Scientific Reports
|
July 3, 2023
The genomic and transcriptomic landscape of advanced renal cell cancer for individualized treatment strategies
K de Joode, W S van de Geer, G J L H van Leenders, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 5, 2014
Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients
B Mostert, A M Sieuwerts, J Kraan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 1, 2019
Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients
S B van Waalwijk van Doorn-Khosrovani, A Pisters-van Roy, L van Saase, et al.
Page
of 10